Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Team Grant: Bone Health - LOI

University of British Columbia

$10,000.00

Progesterone, Bone Formation & Strength

EF 2011-12

Résumé
Osteoporosis and fractures cause pain and disability. Annual fracture costs are now $1.9 billion1. This Bone Team is led by Dr. Jerilynn Prior(BC)and clinician-scientists from coast to coast. Fractures occur because bone loss is faster than its replacement-this weakens bone. Bone loss and gain are linked. So all therapies that stop bone loss also stop bone gain. Previous research by Prior and others show that progesterone increases new bone formation. A forearm "pQCT" test measures bone strength that predicts future fracture. This Team proposes two 2-year studies testing progesterone vs./with usual osteoporosis therapies while measuring bone density & pQCT. These are the 1st studies of pQCT and progesterone. Bone loss occurs in women with hypothalamic amenorrhea or regular cycles & unseen stress-related problems with egg release/low progesterone. These reversible changes are treated with birth control pills (Pills). Young women, ages18-35, of normal weight will have a 50:50 chance of taking progesterone for 14 days/cycle or Pills. A previous Prior study showed a 2% 1-year bone gain with a progesterone-like therapy-44% resumed normal periods. The expectation is that cyclic progesterone will cause pQCT bone gain & cycle recovery-Pills will not. Early postmenopausal women are rapidly losing bone. Women at moderate 10-year fracture risk, ages 45-60, of normal/overweight will all be treated with a bisphosphonate, a standard bone therapy. All will also have a 50:50 chance of taking progesterone or placebo. The expectation is that those who take bisphosphonate plus progesterone will gain more pQCT strength than those on bisphosphonate alone. This Team Bone research will discover new knowledge to share with the public and health providers using on-line, government agencies and physician and consumer education. This Team will generate new information to improve bone strength and fracture prevention for all Canadians. 1www.osteoporosis.ca/index.php/ci_id/8867/la_id/1.htm
Programme
Team Grant: Bone Health - LOI
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
230223
Name
Prior Jerilynn C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Team Grant: Bone Health - LOI
Projecttitle
Progesterone, Bone Formation & Strength
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Team Grant: Bone Health - LOI
Keyworddelim
Bone Health; Osteoporosis; Progesterone
Abstract
Osteoporosis and fractures cause pain and disability. Annual fracture costs are now $1.9 billion1. This Bone Team is led by Dr. Jerilynn Prior(BC)and clinician-scientists from coast to coast. Fractures occur because bone loss is faster than its replacement-this weakens bone. Bone loss and gain are linked. So all therapies that stop bone loss also stop bone gain. Previous research by Prior and others show that progesterone increases new bone formation. A forearm "pQCT" test measures bone strength that predicts future fracture. This Team proposes two 2-year studies testing progesterone vs./with usual osteoporosis therapies while measuring bone density & pQCT. These are the 1st studies of pQCT and progesterone. Bone loss occurs in women with hypothalamic amenorrhea or regular cycles & unseen stress-related problems with egg release/low progesterone. These reversible changes are treated with birth control pills (Pills). Young women, ages18-35, of normal weight will have a 50:50 chance of taking progesterone for 14 days/cycle or Pills. A previous Prior study showed a 2% 1-year bone gain with a progesterone-like therapy-44% resumed normal periods. The expectation is that cyclic progesterone will cause pQCT bone gain & cycle recovery-Pills will not. Early postmenopausal women are rapidly losing bone. Women at moderate 10-year fracture risk, ages 45-60, of normal/overweight will all be treated with a bisphosphonate, a standard bone therapy. All will also have a 50:50 chance of taking progesterone or placebo. The expectation is that those who take bisphosphonate plus progesterone will gain more pQCT strength than those on bisphosphonate alone. This Team Bone research will discover new knowledge to share with the public and health providers using on-line, government agencies and physician and consumer education. This Team will generate new information to improve bone strength and fracture prevention for all Canadians. 1www.osteoporosis.ca/index.php/ci_id/8867/la_id/1.htm
Competitiondate
201104
Approvedterm2
1 yr 0 mth
Pinamesdelim
Prior, Jerilynn C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $10,000~ $0~